This article is more than 5 years old. Information may no longer be current.
Nicox completes enrollment in blepharitis treatment trial
Enrollment has been completed in a phase 2 clinical trial of NCX 4251, a treatment candidate for acute exacerbations of blepharitis, Nicox announced in a press release.
The objective of the multicenter, dose-escalating trial is to select the dose of NCX 4251 — an ophthalmic suspension of fluticasone propionate nanocrystals — to advance into a phase 2b clinical trial, the release said.
“NCX 4251 is an innovative product candidate, both through the choice of active ingredient and form of application, which targets the unmet need in acute exacerbations of blepharitis,” Michele Garufi, Nicox chairman and CEO, said in the release. “We estimate that the addressable market for this indication in the U.S. alone may be more than $700 million annually, rising to over $1 billion by 2024.”
Topline data from the trial are expected in the fourth quarter of this year.